| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Pharmacology, The University of Missouri-Kansas City, Kansas City, Missouri 64108
 |
ABSTRACT |
|---|
 TOP
 ABSTRACT
 INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Experiments were performed to determine if
glucocorticoids potentiate central hypertensive actions of ANG
II. Male Sprague-Dawley rats were treated for 3 days to 3 wk
with corticosterone (Cort). Experiments were performed in conscious
rats that had previously been instrumented with arterial and venous
catheters and an intracerebroventricular guide cannula in a lateral
ventricle. Baseline arterial pressure (AP) was greater in Cort-treated
rats than in control rats (119 ± 2 vs. 107 ± 1 mmHg,
P < 0.01). Microinjection of ANG II
intracerebroventricularly produced a significantly larger increase in
AP in Cort-treated rats than in control rats. For example, at 30 ng ANG
II, AP increased by 23 ± 1 and 16 ± 2 mmHg in Cort-treated
and control rats, respectively (P < 0.01).
Microinjection of an angiotensin type 1 receptor antagonist significantly decreased AP (
6 ± 2 mmHg) and heart rate
(26 ± 7 beats/min) in Cort-treated but not control rats.
Increases in AP produced by intravenous administration of ANG II were
not different between control and Cort-treated rats. Intravenous
injections of ANG II antagonist had no significant effects on mean AP
or heart rate in control or Cort-treated rats. Therefore, a sustained increase in plasma Cort augments the central pressor effects of ANG II
without altering the pressor response to peripheral administration of
the hormone.
corticosterone; hypertension; sympathetic nervous system; central nervous system; intracerebroventricular
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
IT IS WELL ESTABLISHED THAT glucocorticoids are essential for normal control of arterial pressure (15), and there is growing recognition that they participate in the pathogenesis of essential hypertension (5, 27, 38, 43-45). It is known that glucocorticoids influence arterial pressure regulation through multiple peripheral mechanisms, including upregulation of both the sympathetic nervous system and the renin-angiotensin system (31). Both the renin-angiotensin system and the sympathetic nervous system are thought to contribute to the development and maintenance of human hypertension through interrelated peripheral and central mechanisms (30, 39, 41). However, there is no consensus regarding the effects of glucocorticoids on central neural control of the circulation, and the effects of glucocorticoids on central nervous system angiotensin-mediated mechanisms of hypertension are not known.
Evidence that glucocorticoids functionally upregulate the sympathetic nervous system includes results from previous studies showing that exogenous administration or endogenous overproduction of glucocorticoids in rats or humans results in exaggerated blood pressure and vascular responses to adrenergic agonists (7, 16, 28, 31, 45). It has also been reported that glucocorticoid treatment increased the magnitude of pressure reduction following ganglionic blockade (22). However, the effect of glucocorticoids on central regulation of sympathetic outflow is not fully elucidated. Both increases and decreases in directly measured sympathetic nerve activity in response to glucocorticoids have been reported (8, 10, 14, 20, 24, 32, 35, 40). The relative importance of changes in sympathetic nerve activity vs. vascular reactivity in the development of glucocorticoid hypertension has not been established.
A role for the renin-angiotensin system in the mechanism of glucocorticoid hypertension has also been demonstrated. Several investigators have reported that intravenous administration of an ANG II antagonist attenuated glucocorticoid-induced hypertension in humans and rats (6, 22, 42). Glucocorticoids have been shown to augment the increase in arterial pressure in response to peripheral (intravenous) administration of ANG II in both rats and humans (22, 31, 47). Glucocorticoids also increase the expression of angiotensin type 1 (AT1) receptors both in the peripheral vasculature and in the central nervous system (1, 4, 31, 36), and they elevate ANG II-converting enzyme (30). In addition, elevated peripheral angiotensinogen has been reported in patients with endogenous overproduction of cortisol and in experimental animals treated with glucocorticoids (21, 22), and elevated central angiotensinogen has been observed in rats (4). Functionally, it has been demonstrated that glucocorticoids potentiate ANG II-induced drinking (13).
ANG II elevates arterial pressure by several mechanisms, as reviewed by Saavedra (30). Peripheral administration of ANG II produces direct and immediate vasoconstriction of arterioles and increases release of catecholamines by acting presynaptically on sympathetic nerve terminals. In addition, ANG II acts in the central nervous system as a neurotransmitter, elevating sympathetic nerve activity, stimulating vasopressin release, and attenuating the arterial baroreceptor reflex.
The present experiments were performed to test the hypothesis that glucocorticoids potentiate central actions of ANG II to increase arterial pressure. In these experiments, elevations in plasma glucocorticoid concentrations were achieved by implantation of a subcutaneous pellet of corticosterone (Cort) that approximately doubled plasma Cort concentration. After 3-21 days of glucocorticoid treatment, ANG II or an AT1-receptor antagonist was administered into the cerebral ventricles of control and glucocorticoid-treated conscious rats, and changes in arterial pressure and heart rate were recorded. For comparison, the effects of the glucocorticoid treatment on peripheral actions of ANG II and phenylephrine to increase arterial pressure were also determined.
| |
METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
These experiments were performed using 58 male Sprague-Dawley rats purchased from either Harlan or Charles River Laboratories. The experiments were performed either at the University of Texas Health Science Center, San Antonio (13 rats) or at The University of Missouri, Kansas City (45 rats). All animals were housed in U. S. Department of Agriculture and American Association for Accreditation of Laboratory Animal Care accredited animal care facilities and were provided food and water ad libitum. The rats were on a normal sodium diet (0.12 mmol/g in San Antonio and 0.17 mmol/g in Kansas City).
Surgical Procedures
General. All surgical procedures were performed using aseptic technique, and the depth of anesthesia was always maintained to eliminate the withdrawal reflex to pinch of the hind paw. After all surgeries, rats were placed in clean recovery cages.
Intracerebroventricular guide cannula. Intracerebroventricular guide cannulas extending 2.5 mm below the surface of the skull were either manufactured in the laboratory using 23-gauge steel tubing or purchased from Plastics One (Roanoke, VA). Surgery to implant the guide cannula was done under Dormitor (0.5 mg/kg ip metatomidine hydrochloride; Pfizer Animal Health, Exton, PA) and Vetame (75 mg/kg ip ketamine hydrochloride; Solvay Animal Health, Mendoda Hts., MN) anesthesia (12). The rat was positioned in a stereotaxic instrument, and the skull was exposed through a midline incision. A hole was drilled in the skull at 1.5 mm lateral (left or right) and 1.0 to 1.1 mm caudal to bregma for insertion of the guide cannula. Two to four anchoring screws were placed in the skull, the guide cannula was inserted, and dental cement was used to keep the cannula in place. After completion of the surgery, the guide cannula was plugged using a "dummy" internal cannula, and the anesthetic antagonist Antisedan (1 mg/kg ip atipamezole hydrochloride) was administered to hasten recovery of the animal from anesthesia (12). Rats were allowed 1-2 wk to recover before implantation of arterial and venous catheters for measuring arterial pressure, obtaining blood samples for the measurement of plasma Cort, and administration of drugs.
Arterial and venous catheters. Surgery to implant catheters into the femoral artery and vein was performed under isoflurane or methoxyflurane anesthesia. The femoral artery and vein were isolated through a small skin incision and catheterized with Teflon-tipped Tygon tubing in the artery and PE-50 tubing, pulled out to a finer tip, in the vein. The catheters were tunneled under the skin and exteriorized at the back of the neck. The incision was sutured closed, and the catheters were anchored to the skin. The arterial catheter was filled with sterile heparin (1,000 U/ml), and the venous catheter was filled with sterile heparinized saline (20 U/ml).
Cort treatment. Increases in plasma Cort concentration were produced (n = 31) by subcutaneous implantation of Cort pellets weighing 127 ± 5 mg. Pellets were made using an established technique (3, 33). Briefly, Cort was liquefied and pipetted into a mold designed specifically for manufacturing the pellets (Ted Pella, Redding, CA). Surgery for implantation of the pellets was performed either at the time of intracerebroventricular cannulation, at the time of the femoral catheterization, or in a separate surgery under isoflurane or methoxyflurane anesthesia. A small skin incision was made in the dorsal lumbar region, and a pellet was inserted subcutaneously. The incision was sutured closed. Experiments were performed 3 to 22 days following implantation of the pellets.
During many experiments, plasma samples (200 µl) for the measurement of plasma Cort were obtained before the initiation of any experimental protocol. The blood samples were centrifuged at 4°C, and the plasma was stored at20°C until being assayed. Plasma Cort was determined
as previously described (33) using a commercially
available kit (ImmuChem double antibody Cort I125 RIA kit;
ICN Biomedicals, Costa Mesa, CA). Exogenous Cort decreases thymus and
adrenal weight (3). Therefore, at the conclusion of each
experiment, the animals were euthanized with an overdose of isoflurane,
then the thymus and adrenal glands were removed, patted dry, and
weighed. For data analysis, thymus and adrenal weights were normalized
to body weight.
Experimental Protocols
General. The experiments were performed in conscious rats at least 2 days, but usually 3 or more days, after implantation of the catheters. The rats were brought to the laboratory in their home cages between 7 and 8 AM, and their arterial catheters were connected to pressure transducers (Maxxim Medical, Athens, TX). The rats were allowed a minimum of 1 h to acclimatize to the laboratory setting before the baseline blood sample was obtained. Blood samples were collected between 9 and 11 AM. After the collection of the blood sample, at least 15 min elapsed before initiation of the experimental protocol. There was a total of five experimental protocols involving the intracerebroventricular or intravenous administration of drugs: 1) intracerebroventricular ANG II, 2) intracerebroventricular ANG II antagonist, 3) intravenous ANG II, 4) intravenous ANG II antagonist, and 5) intravenous phenylephrine. Some rats were used in more than one protocol.
Intracerebroventricular microinjections.
Microinjections were made by inserting an internal cannula into the
guide cannula at least 15 min before the injection. The internal
cannula projected either 1.0 or (usually) 1.4 mm past the end of the
guide cannula. All drugs administered into the cerebral ventricles were
dissolved in 5 µl of sterile artificial cerebral spinal fluid of the
following composition (in mM): 128 NaCl, 2.6 KCl, 1.3 CaCl2, 0.9 MgCl2, 20 NaHCO
Intravenous injections. All drugs administered intravenously were dissolved in sterile 0.9% sodium chloride in volumes of 400 µl or less. ANG II was administered at doses of 0 (vehicle), 1, 3, 10, 30, and 100 ng/kg. Each animal included in this protocol received all doses of ANG II. The angiotensin-receptor antagonist L-158809 (0.1 mg/kg) was administered following a 30-min baseline period. Arterial pressure and heart rate were recorded continuously throughout the baseline period and for 60 min following administration of ANG II antagonist. In some rats, the effectiveness of the ANG II antagonist was tested by administration of intracerebroventricular ANG II (30 ng, n = 7) and/or intravenous ANG II (30 ng/kg, n = 12).
As described in the introduction (30), the rapid increase in pressure in response to the intracerebroventricular injection of ANG II is due, in part, to activation of the sympathetic nervous system. Under some conditions, glucocorticoids can increase vascular responsiveness to adrenergic stimulation (7, 22, 31). Therefore, any enhancement of the pressure response to intracerebroventricular ANG II in glucocorticoid-treated animals could be due to an increased vasoconstrictor response to sympathetic activation, rather than an increase in sympathetic nerve activity. To eliminate this as a possible explanation for the results, the increase in pressure in response to intravenous administration of the
-adrenergic receptor agonist phenylephrine was compared in control
and Cort-treated rats. Phenylephrine was administered at doses of 0 (vehicle), 0.1, 0.3, and 1 µg/kg. Each animal included in this
protocol received all doses of phenylephrine.
Data Analysis
Cardiovascular data. Pulsatile arterial pressure was measured from the arterial catheter using a pressure transducer (Maxxim Medical) connected to a bridge amplifier (World Precision Instruments, Sarasota, FL). The output from the bridge amplifier was fed into a MacLab (ADInstruments) analog-to-digital processor connected to a Macintosh computer. Mean arterial pressure (MAP) and heart rate were determined online from the pulsatile pressure using the MacLab software. Baseline values for MAP and heart rate were determined before administration of the antagonist or the "0" dose of agonist. With the intracerebroventricular administration of ANG II, not all rats received the "0" dose. For this protocol, average baseline MAP and heart rate were determined for each animal. To quantify the responses to administration of ANG II or phenylephrine, average values for MAP and heart rate were determined just before and during the peak of the rapid response to administration of each dose of each agonist, and the changes in MAP and heart rate were calculated. To quantify the responses to administration of ANG II antagonist, values for MAP and heart rate were determined during a 30-min baseline period and for 60 min following administration of ANG II antagonist or vehicle. Changes in MAP and heart rate in response to the antagonist were then calculated.
Statistics. There was no observed relationship between any measured values or responses and the duration of Cort treatment, so all the data for Cort-treated rats were combined for presentation and analysis. Values for MAP, heart rate, plasma Cort, and thymus and adrenal weights were analyzed by one- or two-way ANOVA as appropriate. Effects of ANG II antagonist were analyzed over time using the absolute values for MAP and heart rate. Responses to agonists were analyzed using calculated changes from baseline. Repeated-measures analysis was used for all within-subject variables. For post hoc analysis, Tukey's test was used for between-subject variables, and least-square means were used for within-subject variables. Significance was accepted at P < 0.05. Values are expressed as means ± SE.
| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
The Cort treatment used in these experiments approximately doubled plasma Cort from 3.13 ± 0.56 µg/dl in control rats (n = 19) to 7.11 ± 0.89 µg/dl in Cort-treated rats (n = 25, P < 0.01). Cort treatment reduces both thymus and adrenal weights, so these weights were used to assess the physiological effectiveness of the Cort treatment. Cort treatment significantly reduced thymus weight (in mg/kg of body wt) from 872 ± 92 mg/kg in control rats to 626 ± 29 mg/kg in the Cort-treated rats (P < 0.01). Adrenal weight was also reduced in Cort-treated rats, going from 182 ± 12 mg/kg in control rats to 126 ± 11 mg/kg in Cort-treated rats (P < 0.01). Body weight at the time of the experiments did not differ significantly between control (395 ± 5 g) and Cort-treated rats (382 ± 5 g).
Overall, average MAP measured during the baseline period of the
experiments was higher in the Cort-treated rats (119 ± 2 mmHg, n = 31) than in the control rats (107 ± 1 mmHg,
n = 27, P < 0.01). Cort treatment had
no significant effect on baseline heart rate, which was 341 ± 4 vs. 353 ± 7 beats/min in control vs. Cort rats, respectively.
Intracerebroventricular administration of ANG II (10, 30, 100, and 300 ng) produced dose-dependent increases in arterial pressure in both
control and Cort-treated rats (P < 0.01; Fig.
1, top). Pretreatment of rats
with Cort significantly enhanced the pressure response to ANG II at all
doses of ANG II (P < 0.02 for all doses except
vehicle). The increase in arterial pressure produced a reflex reduction
in heart rate (P < 0.01) that was not significantly
greater in Cort-treated rats, despite the larger increase in arterial
pressure (Fig. 1, bottom).
|
The above data demonstrate that Cort enhanced the pressure response to
central administration of exogenous ANG II. To determine if Cort
enhanced the contribution of endogenous central ANG II to the
maintenance of arterial pressure and heart rate, an ANG II antagonist
was administered intracerebroventricularly. Either L-158809
(n = 9) or losartan (n = 6) was
administered intracerebroventricularly to control and Cort-treated
rats. In Cort-treated rats, ANG II antagonist produced a small but
significant reduction in arterial pressure that reached a maximum of
5.9 ± 1.5 mmHg at 30-40 min following administration of
ANG II antagonist (Fig. 2,
top; P < 0.01). ANG II antagonist also
reduced heart rate in Cort-treated rats by a maximum of 26 ± 7 beats/min at 30-40 min following administration of ANG II
antagonist (Fig. 2, bottom; P < 0.01). ANG
II antagonist had no significant effect on arterial pressure or heart
rate in control rats. The effectiveness of the ANG II antagonist was
tested in seven rats that received 30 ng of ANG II
intracerebroventricularly before and at least 60 min after administration of ANG II antagonist. The average increase in arterial pressure before the ANG II antagonist was 24 ± 3 mmHg
(P < 0.01), whereas after ANG II antagonist arterial
pressure did not change significantly in response to
intracerebroventricular ANG II (1 ± 1 mmHg). To determine if the
intracerebroventricular administration of ANG II antagonist was
blocking peripheral receptors, intravenous ANG II (30 ng/kg) was
administered after intracerebroventricular administration of ANG II
antagonist in six rats. The average increase in arterial pressure in
response to intravenous ANG II was 54 ± 1 mmHg (P < 0.01). In another experimental protocol (Fig.
3), intravenous ANG II (30 ng/kg)
increased MAP by 41 ± 3 mmHg in control rats in the absence of
intracerebroventricular ANG II antagonist. Therefore,
intracerebroventricular ANG II antagonist did not block peripheral
actions of ANG II in these experiments.
|
|
Several investigators have reported that glucocorticoids increase the
peripheral vasoconstrictor effects of ANG II (22, 31, 47).
To determine if the dose of Cort used in this study was sufficient to
increase vascular responsiveness to ANG II, ANG II was administered
intravenously to control and Cort-treated rats. Intravenous
administration of ANG II caused a dose-dependent increase in arterial
pressure (Fig. 3, top; P < 0.01), the
magnitude of which was not significantly affected by Cort treatment.
The magnitude of the reflex reduction in heart rate was also unaffected by Cort treatment (Fig. 3, bottom). To confirm that
the Cort treatment did not alter the contribution of peripheral ANG II
to the maintenance of arterial pressure, the ANG II antagonist L-158809
was administered intravenously. Arterial pressure and heart rate were
monitored for 60 min following administration of the ANG II antagonist, and the data were averaged into 10-min periods. The ANG II antagonist had no effect on either arterial pressure or heart rate in either control or Cort-treated rats (Fig. 4). To
test the effectiveness of the intravenous ANG II antagonist, the
arterial pressure response to 30 ng/kg of intravenous ANG II was
determined before and after intravenous administration of L-158809 in
12 rats. The change in arterial pressure was 39 ± 3 mmHg
(P < 0.01) before and 1 ± 1 mmHg (not
significant) after the antagonist. The arterial pressure response to
intracerebroventricular ANG II (30 ng) was also determined before and
after intravenous ANG II antagonist (n = 7). The
increase in arterial pressure in response to intracerebroventricular
ANG II was significantly reduced after peripheral administration
of the antagonist (21 ± 2 vs. 15 ± 2 mmHg,
P < 0.01). This reduction in the
intracerebroventricular response could have been due to a decrease
in norepinephrine release at peripheral sympathetic nerve
terminals rather than to a central action of the antagonist (30).
|
Glucocorticoids have also been shown to increase vascular
responsiveness to adrenergic agonists (7, 16, 28, 31, 45). Because central ANG II increases arterial pressure in part by activation of the sympathetic nervous system, it is possible that the
enhanced effect of ANG II in the Cort-treated rats was due to an
increase in vascular responsiveness to adrenergic stimulation, rather
than to an increase in nerve activity. To investigate the effects of
Cort treatment on vascular sensitivity to -adrenergic agonists in
this study, intravenous phenylephrine was administered to control and
Cort-treated rats. Figure 5 shows that
phenylephrine produced equivalent increases in arterial pressure in
control and Cort-treated rats, indicating that increased end-organ
responsiveness could not account for enhanced effects of
intracerebroventricular ANG II on arterial pressure in Cort-treated
rats.
|
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Experiments were performed to test the hypothesis that glucocorticoids augment hypertensive actions of ANG II in the central nervous system. The results demonstrate that intracerebroventricular administration of ANG II increased arterial pressure by a larger amount in Cort-treated rats than in control rats (Fig. 1). Furthermore, intracerebroventricular administration of an AT1-receptor antagonist decreased both arterial pressure and heart rate in Cort-treated rats, but had no effect on these parameters in control rats (Fig. 2). By comparison, this dose of Cort, which only doubled plasma Cort concentration, had no effect on peripheral vascular actions of ANG II to increase arterial pressure (Fig. 3). Additionally, peripheral administration of an AT1-receptor antagonist had no significant effect on arterial pressure or heart rate in either control or Cort-treated rats during the 60 min for which data were recorded (Fig. 5). Therefore, we conclude that Cort enhanced central effects of ANG II to increase arterial pressure and raise heart rate. Glucocorticoids have been shown to augment the increase in blood pressure in response to peripheral (intravenous) administration of ANG II in both humans with endogenous overproduction of glucocorticoids and in glucocorticoid-treated rats (22, 31, 47). Subjects in these studies had larger glucocorticoid-induced increases in arterial pressure and/or plasma glucocorticoid concentrations than the rats in the present study. Thus the data also support the conclusion that central control of arterial pressure by ANG II is more sensitive to the effects of Cort than is peripheral control of arterial pressure by ANG II.
Doses for ANG II were chosen based on ranges used in the literature and were estimated to provide a range of dose-dependent increases in arterial pressure. In retrospect, one or two lower intracerebroventricular doses could have been tested. Doses for intracerebroventricular ANG II were not normalized to body weight, as seems to be the convention in the literature (e.g., Ref. 46). However, because there was no significant difference in body weight between control and Cort-treated rats at the time of the experiments, the lack of normalization does not affect the interpretation of the data. The rats weighed ~400 g, making the doses of intracerebroventricular ANG II range from 25 to 750 ng/kg. The two lower doses of intracerebroventricular ANG II were thus in the range of the two highest doses of intravenous ANG II. At these comparable mass doses of ANG II, there was a significant augmentation of the pressor response to intracerebroventricular, but not intravenous, ANG II. Thus the difference in dose range also does not alter interpretation of the results.
Intracerebroventricular administration of ANG II increases arterial pressure both by activating the sympathetic nervous system and by stimulating vasopressin release, with the sympathetic nervous system accounting for most of the immediate rapid increase in pressure (11). In these experiments, the peak of the rapid arterial pressure increase following intracerebroventricular ANG II was measured. Moreover, glucocorticoids inhibit the release of vasopressin (29). Although additional experiments are needed to unequivocally determine the mechanism, it is very likely that the effects of Cort to enhance central actions of ANG II are due to augmented activation of the sympathetic nervous system rather than to enhanced vasopressin release.
On the basis of the results from previous studies, glucocorticoids
could augment ANG II-mediated activation of the sympathetic nervous
system by more than one mechanism. First, glucocorticoids could
increase peripheral vascular responsiveness to -adrenergic stimulation, as has been shown by some investigators (7, 16, 28,
31, 45). However, in these experiments, Cort treatment had no
effect on the magnitude of arterial pressure increases produced by
phenylephrine. A more likely explanation for the results presented here
is that glucocorticoids can increase efferent sympathetic nerve
activity through an ANG II-dependent mechanism. Previous studies have
reported both inhibitory and stimulatory effects of glucocorticoids on
sympathetic nerve activity (8, 10, 14, 20, 24, 32, 35,
40). The lack of agreement in these data suggests a complex
effect of glucocorticoids on sympathetic outflow. One study has
reported that acute intracerebroventricular administration of
hydrocortisone increased renal sympathetic nerve activity by a
mechanism that was blocked by central administration of an ANG II
antagonist (40). Further experiments are needed to
determine if chronic administration of Cort also stimulates sympathetic
nerve activity through an ANG II-dependent mechanism.
In these experiments, ANG II and ANG II antagonist were administered into the cerebral ventricles rather than into a specific area of the central nervous system. Intracerebroventricular administration of ANG II through the lateral ventricle produces an increase in sympathetic nerve activity primarily by activating receptors in the anterior region of the third ventricle (30). These receptors are close to the site of administration of ANG II and mediate potent effects of ANG II on arterial pressure. However, ANG II also activates receptors in other areas of the brain (30). For example, activation of ANG II receptors in the nucleus of the solitary tract attenuates the arterial baroreceptor reflex (19, 26, 30), and in the rostral ventral lateral medulla it increases sympathetic outflow (18). In addition, glucocorticoid type II receptors are found in the nucleus of the solitary tract and the rostral ventral lateral medulla (2). With intracerebroventricular administration of nonpeptide ANG II antagonists in this study, the maximum reductions in arterial pressure and heart rate in Cort-treated rats were not observed until 30-40 min after administration of the antagonist. This suggests the possibility that cumulative blockade of ANG II receptors at multiple central nervous system loci, or a cascade of effects following blockade of forebrain receptors, may have contributed to the decrease in arterial pressure and heart rate in the Cort-treated rats.
The maximum decrease in arterial pressure following
intracerebroventricular administration of ANG II antagonist to
Cort-treated rats was only 5.9 ± 1.5 mmHg, whereas the
difference in average baseline arterial pressure in control vs.
Cort-treated rats was 10.8 mmHg. Therefore, the intracerebroventricular
administration of ANG II antagonist reversed just 55% of the increase
in arterial pressure caused by Cort treatment. Several mechanisms could
account for this. First, the antagonist may not have blocked all
central nervous system sites at which Cort acts through ANG II
receptors to increase arterial pressure. Second, the effect of the ANG
II antagonist to decrease arterial pressure was only followed for 1 h. Because ANG II has the capability of activating early
immediate genes (17), some actions of ANG II on neuronal
function may take longer than 1 h to reverse. Furthermore, events
leading to gene transcription triggered by ANG II may not be reversible
by an ANG II antagonist once the increase in gene transcription has been triggered. In any case, there is general agreement that the mechanism of glucocorticoid-induced hypertension is multifactorial, and
it would not be expected that blockade of a single receptor type would
completely reverse a glucocorticoid-induced increase in arterial pressure.
Intracerebroventricular administration of an ANG II antagonist to
Cort-treated rats decreased heart rate by a maximum of 26 beats/min,
despite the fact that the reduction in arterial pressure should have
caused a baroreflex-mediated increase in heart rate. The
antagonist had no effect on heart rate in control rats. However, there was no significant difference in baseline heart rate between control and Cort-treated rats. These results suggest that Cort may have
an effect to elevate heart rate through an ANG II-dependent mechanism.
However, the increase in arterial pressure caused by Cort may activate
reflex or other mechanisms that return heart rate back toward control
values, even in the presence of baroreceptor reflex resetting.
Perspectives
There is increasing evidence that abnormalities in glucocorticoid receptors, metabolism, and responsiveness contribute to the mechanisms of human hypertension (5, 27, 38, 43-45). Glucocorticoids are also elevated by stress, an accepted risk factor for hypertension. Peripheral mechanisms of glucocorticoid-induced hypertension have been extensively investigated, whereas much less is known regarding central effects of glucocorticoids on arterial pressure regulation. In contrast, ANG II is an established mediator of hypertension, and ANG II inhibitors and antagonists comprise a major class of antihypertensive pharmaceuticals (30). The data reported here demonstrate for the first time that glucocorticoids enhance central actions of ANG II to increase arterial pressure at a dose that does not affect peripheral vasoconstriction mediated by ANG II or-adrenergic receptors. Thus even slightly elevated levels of
glucocorticoids could act in concert with other mechanisms to produce
central nervous system-mediated hypertension.
Understanding the mechanisms of glucocorticoid-induced hypertension has additional relevance in light of reports that in humans and experimental animals, exposure to elevated glucocorticoids during critical prenatal periods increases plasma glucocorticoid levels in the adult offspring (25). These offspring are also at an increased risk for hypertension in adulthood (9, 34). Increased activation of the renin-angiotensin system has been suggested as a mechanism for the adult hypertension (23). Glucocorticoids are administered to pregnant women, and maternal stress, poor diet, and other conditions can increase endogenous glucocorticoids in pregnancy. Thus the clinical relevance of understanding the effects of glucocorticoids on central regulation of arterial pressure by ANG II and other hormones and neurotransmitters is significant.
| |
ACKNOWLEDGEMENTS |
|---|
The authors thank M. Herrera-Rosales for excellent technical assistance with the experiments performed at the University of Texas Health Science Center in San Antonio. L-158809 was the generous gift of Merck Research Laboratories.
| |
FOOTNOTES |
|---|
This work was supported by National Institutes of Health Grant HL-56112.
Address for reprint requests and other correspondence: D. A. Scheuer, Dept. of Pharmacology, The Univ. of Missouri-Kansas City, 2411 Holmes St., Rm. MG 111, Kansas City, MO 64108 (E-mail: scheuerd{at}umkc.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 2 November 2000; accepted in final form 9 February 2001.
| |
REFERENCES |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1.
Aguilera, G,
Kiss A,
and
Luo X.
Increased expression of type I angiotensin receptors in the hypothalamic paraventricular nucleus following stress and glucocorticoid administration.
J Neuroendocrinol
7:
775-783,
1995[Web of Science][Medline].
2.
Ahima, RS,
and
Harlan RE.
Charting of the type II glucocorticoid receptor-like immunoreactivity in the rat central nervous system.
Neuroscience
39:
579-604,
1990[Web of Science][Medline].
3.
Akana, SF,
Scribner KA,
Bradbury MJ,
Strack AM,
Walker CD,
and
Dallman MF.
Feedback sensitivity of the rat hypothalamo-pituitary-adrenal axis and its capaciy to adjust to exogenous corticosterone.
Endocrinology
131:
585-594,
1992
4.
Bennemann, B,
Lippoldt A,
Aguirre JA,
Cintra A,
and
Metzger R.
Glucocorticoid regulation of angiotensinogen gene expression in discrete areas of the male rat brain.
Neuroendocrinology
57:
856-862,
1993[Web of Science][Medline].
5.
Connell, JMC,
Kenyon CJ,
Ingram M,
Holloway C,
Jamieson A,
Panarelli M,
Inglis G,
and
Fraser R.
Corticosteroids in essential hypertension: multiple candidate loci and phenotypic variation.
Clin Exp Pharmacol Physiol
23:
369-374,
1996[Web of Science][Medline].
6.
Dalakos, TG,
Elias A,
Anderson GH, Jr,
Streeten DHP,
and
Schroeder ET.
Evidence for an angiotensinergic mechanism of the hypertension of Cushing's Syndrome.
J Clin Endocrinol Metab
46:
114-118,
1978
7.
Darlington, DN,
Kaship K,
Keil LC,
and
Dallman MF.
Vascular responsiveness in adrenalectomized rats with corticosterone replacement.
Am J Physiol Heart Circ Physiol
256:
H1274-H1281,
1989
8.
Davis, SN,
Shavers C,
Costa F,
and
Mosqueda-Garcia R.
Role of cortisol in the pathogenesis of deficient counterregulation after antecedent hypoglycemia in normal humans.
J Clin Invest
98:
680-691,
1996[Web of Science][Medline].
9.
Dodic, M,
May CN,
Wintour EM,
and
Coghlan JP.
An early prenatal exposure to excess glucocorticoid leads to hypertensive offspring in sheep.
Clin Sci (Colch)
94:
149-155,
1998[Medline].
10.
Dodt, C,
Keyser B,
Molle M,
Fehm HL,
and
Elam M.
Acute suppression of muscle sympathetic nerve activity by hydrocortisone in humans.
Hypertension
35:
758-763,
2000
11.
Falcon, JC,
Phillips MI, II,
Hoffman WE,
and
Brody MJ.
Effects of intraventricular angiotensin II mediated by the sympathetic nervous system.
Am J Physiol Heart Circ Physiol
235:
H392-H399,
1978.
12.
Flecknell, P.
Medetomidine and atipamezole: potential uses in laboratory animals.
Lab Anim
26:
21-24,
1997.
13.
Ganesan, R,
and
Sumners C.
Glucocorticoids potentiate the dipsogenic action of angiotensin II.
Brain Res
499:
121-130,
1989[Web of Science][Medline].
14.
Golczynska, A,
Lenders WM,
and
Goldstein DS.
Glucocorticoid-induced sympathoinhibition in humans.
Clin Pharmacol Ther
58:
90-98,
1995[Web of Science][Medline].
15.
Grunfeld, JP.
Glucocorticoids in blood pressure regulation.
Horm Res
34:
111-113,
1990[Web of Science][Medline].
16.
Grunfeld, JP,
and
Eloy L.
Glucocorticoids modulate vascular reactivity in the rat.
Hypertension
10:
608-618,
1987
17.
Herbert, J,
Fosling ML,
Howes SR,
Stacey PM,
and
Shires HM.
Regional expression of c-fos antigen in the basal forebrain following intraventricular infusion of angiotensin and its modulation by drinking either water or saline.
Neuroscience
51:
867-882,
1992[Web of Science][Medline].
18.
Ito, S,
and
Sved AF.
Blockade of angiotensin receptors in rat rostral ventrolateral medulla removes excitatory vasomotor tone.
Am J Physiol Regulatory Integrative Comp Physiol
270:
R1317-R1323,
1996
19.
Kasparov, S,
Butcher JW,
and
Paton J.
Angiotensin II receptors within the nucleus of the solitary tract mediate the developmental attenuation of the baroreceptor vagal reflex in pre-weaned rats.
J Auton Nerv Syst
74:
160-168,
1998[Web of Science][Medline].
20.
Koyama, S.
Effects of methylprednisolone on renal nerve responses to stimulation of the medullary pressor area in endotoxin-induced hypertension.
Circ Shock
20:
205-215,
1986[Web of Science][Medline].
21.
Krakoff, L,
Nicolis G,
and
Amsel B.
Pathogenesis of hypertension in Cushing's syndrome.
Am J Med
58:
216-220,
1975[Web of Science][Medline].
22.
Krakoff, LR,
Selvadurai R,
and
Sutter E.
Effect of methylprednisolone upon arterial pressure and the renin angiotensin system in the rat.
Am J Physiol
228:
613-617,
1975.
23.
Langley-Evans, SC,
Sherman RC,
Welham SJM,
Nwagwu MO,
Garnerg DS,
and
Jackson AA.
Intrauterine programming of hypertension: role of the renin-angiotensin system.
Biochem Soc Trans
27:
88-93,
1999[Web of Science][Medline].
24.
Lenders, JWM,
Golczynska A,
and
Goldstein DS.
Glucocorticoids, sympathetic activity, and presynaptic alpha 2-adrenoceptor function in humans.
J Clin Endocrinol Metab
80:
1804-1808,
1995[Abstract].
25.
Mathews, SG.
Antenatal glucocorticoids and programming of the developing CNS.
Pediatr Res
47:
291-300,
2000[Web of Science][Medline].
26.
Matsumura, K,
Averill DB,
and
Ferrario CM.
Angiotensin II acts at AT1 receptors in the nucleus of the solitary tract to attenuate the baroreceptor reflex.
Am J Physiol Regulatory Integrative Comp Physiol
275:
R1611-R1619,
1998
27.
Olbinskaya, LI,
Golubev SA,
and
Bolshakova TD.
Influence of benazepril and captopril on blood pressure, glucocorticoids and progesterone in essential hypertensives.
J Hum Hypertens
7:
603-606,
1993[Web of Science][Medline].
28.
Pirpiris, M,
Sudhir K,
Yeung S,
Jennings G,
and
Whitworth JA.
Pressor responsiveness in corticosteroid-induced hypertension in humans.
Hypertension
19:
567-574,
1992
29.
Raff, H.
Glucocorticoid inhibition of neurohypophysial vasopressin secretion.
Am J Physiol Regulatory Integrative Comp Physiol
252:
R635-R644,
1987
30.
Saavedra, JM.
Brain and pituitary angiotensin.
Endocr Rev
13:
329-379,
1992
31.
Saruta, T.
Mechanism of glucocorticoid-induced hypertension.
Hypertens Res
19:
1-8,
1996[Medline].
32.
Scherrer, U,
Vollenweider P,
Randin D,
Jequier E,
Nicod P,
and
Tappy L.
Suppression of insulin-induced sympathetic activation and vasodilation by dexamethasone in humans.
Circulation
88:
388-394,
1993
33.
Scheuer, DA,
and
Mifflin SW.
Chronic corticosterone treatment increases myocardial infarct size in rats with ischemia reperfusion injury.
Am J Physiol Regulatory Integrative Comp Physiol
272:
R2017-R2024,
1997
34.
Seckl, JR.
Physiologic programming of the fetus.
Clin Perinatol
25:
939-962,
1998[Web of Science][Medline].
35.
Segar, JL,
Lumbers ER,
Nuyt AM,
Smith OJ,
and
Robillard JE.
Effect of antenatal glucocorticoids on sympathetic nerve activity at birth in preterm sheep.
Am J Physiol Regulatory Integrative Comp Physiol
274:
R160-R167,
1998
36.
Shelat, SG,
King JL,
Flanagan-Cato LM,
and
Fluharty SJ.
Mineralocorticoids and glucocorticoids cooperatively increase salt intake and angiotensin II receptor binding in rat brain.
Neuroendocrinology
69:
339-351,
1999[Web of Science][Medline].
37.
Siegl, RKS,
Chang RSL,
Mantlo NB,
Chakravarty PKK,
Ondeyka DL,
Greenlee WJ,
Patchett AA,
Sweet CS,
and
Lotti VJ.
In vivo pharmacology of L-158809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
J Pharmacol Exp Ther
262:
139-144,
1992
38.
Soro, A,
Ingram MC,
Tolono G,
Glorioso N,
and
Fraser R.
Mildly raised corticosterone excretion rates in patients with essential hypertension.
J Hum Hypertens
9:
391-393,
1995[Web of Science][Medline].
39.
Sun, MK.
Central neural organization and control of sympathetic nervous system in mammals.
Prog Neurobiol
47:
157-233,
1995[Web of Science][Medline].
40.
Takahashi, H,
Takeda K,
Ashizawa H,
Inoue A,
Yoneda S,
Yoshimura M,
and
Ijichi H.
Centrally induced cardiovascular and sympathetic responses to hydrocortisone in rats.
Am J Physiol Heart Circ Physiol
245:
H1013-H1018,
1983
41.
Thibonniere, M,
and
Schork NJ.
The genetics of hypertension.
Curr Opin Genet Dev
5:
362-370,
1995[Web of Science][Medline].
42.
Waeber, B,
Gavras H,
Bresnahan MR,
Gavras I,
and
Brunner HR.
Role of vasoconstrictor systems in experimental glucocorticoid-hypertension in rats.
Clin Sci (Colch)
65:
255-261,
1983[Medline].
43.
Walker, BR,
Best R,
Shackleton CHL,
Padfield PL,
and
Edwards CRW
Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension.
Hypertension
27:
190-196,
1996
44.
Watt, GCM,
Harrap SB,
Foy CJW,
Holton DW,
Edwards HV,
Davidson HR,
Conner JM,
Lever AF,
and
Fraser R.
Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four-corners approach to the identification of genetic determinants of blood pressure.
J Hypertens
10:
473-482,
1992[Web of Science][Medline].
45.
Whitworth, JA,
Brown MA,
Kelly JJ,
and
Williamson PM.
Mechanisms of cortisol-induced hypertension in humans.
Steroids
60:
76-80,
1995[Web of Science][Medline].
46.
Widdop, RE,
Gardiner SM,
Kemp PA,
and
Bennett T.
Central administration of PD 123319 or EXP-3174 inhibits effects of angiotensin II.
Am J Physiol Heart Circ Physiol
264:
H117-H125,
1993
47.
Yasuda, G,
Shionoiri H,
Umemura S,
Takasaki I,
and
Ishii M.
Exaggerated blood pressure response to angiotensin II in patients with Cushing's Syndrome due to adrenocortical adenoma.
Eur J Endocrinol
131:
582-588,
1994
This article has been cited by other articles:
|
|
 |
|
  A. G. Bechtold, G. Patel, G. Hochhaus, and D. A. Scheuer Chronic blockade of hindbrain glucocorticoid receptors reduces blood pressure responses to novel stress and attenuates adaptation to repeated stress Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2009; 296(5): R1445 - R1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Scheuer, A. G. Bechtold, and K. A. Vernon Chronic Activation of Dorsal Hindbrain Corticosteroid Receptors Augments the Arterial Pressure Response to Acute Stress Hypertension, January 1, 2007; 49(1): 127 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Scheuer, A. G. Bechtold, S. S. Shank, and S. F. Akana Glucocorticoids act in the dorsal hindbrain to increase arterial pressure Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H458 - H467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Stauss Heart rate variability Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R927 - R931. [Full Text] [PDF]
|
|
|
|
|
|
S. S. Shank and D. A. Scheuer Glucocorticoids reduce responses to AMPA receptor activation and blockade in nucleus tractus solitarius Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1751 - H1761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Shade, J. R. Blair-West, K. D. Carey, L. J. Madden, R. S. Weisinger, and D. A. Denton Synergy between angiotensin and aldosterone in evoking sodium appetite in baboons Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2002; 283(5): R1070 - R1078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Segar, T. Van Natta, and O. J. Smith Effects of fetal ovine adrenalectomy on sympathetic and baroreflex responses at birth Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2002; 283(2): R460 - R467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Scheuer and A. G. Bechtold Glucocorticoids modulate baroreflex control of heart rate in conscious normotensive rats Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2002; 282(2): R475 - R483. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
P < 0.05 relative to control group. bpm, beats/min
) or Cort-treated rats (
). Baseline
MAP was significantly greater in Cort-treated than in control rats
(123 ± 6, n = 8 vs. 106 ± 2 mmHg,
n = 7, respectively, P < 0.03).
Baseline heart rate tended to be higher in Cort-treated rats, but the
difference was not significant (345 ± 11 vs. 371 ± 15 beats/min in control vs. Cort rats, respectively). ANG II antagonist
significantly decreased MAP and heart rate in Cort-treated rats only.
*P < 0.05 relative to baseline for that group.
